<DOC>
	<DOC>NCT01652092</DOC>
	<brief_summary>This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies</brief_title>
	<detailed_description>Based on diagnosis and clinical history, a determination of the most appropriate regimen will be made based on the following prep plans: Arm A: Fully Myeloablative Preparative Regimen, Arm B: Reduced Toxicity Ablative Preparative Regimen, Arm C: Reduced Intensity Conditioning, Arm D: No Preparative Regimen</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Granulomatous Disease, Chronic</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hyper-IgM Immunodeficiency Syndrome, Type 1</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Diagnosis of immunodeficiency or histiocytic disorder including the following: Severe combined immunodeficiency (SCID all variants) Second bone marrow transplant (BMT) for SCID (after graft rejection) Omenn's Syndrome Reticular dysgenesis WiskottAldrich syndrome Major histocompatibility complex (MHC) Class II deficiency (bare lymphocyte syndrome) Hyper IgM Syndrome (CD40 Ligand Deficiency) Common variable immunodeficiency (CVID) with severe phenotype Chronic Granulomatous Disease (CGD) Other severe Combined Immune Deficiencies (CID) Hemophagocytic Lymphohistiocytosis (HLH) Xlinked Lymphoproliferative Disease (XLP) ChediakHigashi Syndrome (CHS) Griscelli Syndrome Langerhans Cell Histiocytosis (LCH) Acceptable stem cell sources include: HLA identical or 1 antigen matched sibling donor eligible to donate bone marrow HLA identical or up to a 1 antigen mismatched unrelated BM donor Sibling donor cord blood with acceptable HLA match and cell dose as per current institutional standards Single unrelated umbilical cord blood unit with 02 antigen mismatch and minimum cell dose of &gt;5 x 10^7 nucleated cells/kg as per current institutional guidelines Double unrelated umbilical cord blood units that are: up to 2 antigen mismatched to the patient up to 2 antigen mismatched to each other minimum cell dose of at least one single unit must be ≥ 3.5 x 10^7 nucleated cells/kg combined dose of both units must provide a total cell dose of ≥ 5 x 10^7 nucleated cells/kg Age: 0 to 50 years Adequate organ function and performance status. Exclusion Criteria pregnant or breastfeeding active, uncontrolled infection and/or HIV positive acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>immunodeficiency disorder</keyword>
	<keyword>histiocytic disorder</keyword>
</DOC>